Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 15/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 15/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 15/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 15/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | VNN1 | O95497 | 1/20 | 0.33 |
| ▸ | BTD | P43251 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25418572 | 0.82 | P2RX7 (0.44) | HDAC3HDAC1HDAC2HDAC6P2RX7 | |
| SCHEMBL25418744 | 0.77 | P2RX7 (0.42) | HDAC3HDAC1HDAC2HDAC6P2RX7 | |
| SCHEMBL6472291 | 0.77 | KMT2A (0.40) | P2RX7MAPTRAB9A | |
| SCHEMBL5533343 | 0.73 | HDAC3 (0.36) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL6472501 | 0.72 | HDAC3 (0.38) | HDAC3HDAC1HDAC2HDAC6P2RX7 | |
| SCHEMBL20340463 | 0.68 | SCN10A (0.40) | HDAC6P2RX7 | |
| SCHEMBL2542108 | 0.67 | CYP1A2 (0.50) | — | |
| SCHEMBL193633 | 0.67 | FPR2 (0.48) | P2RX7RAB9A | |
| SCHEMBL17005755 | 0.67 | HDAC3 (0.49) | HDAC3HDAC1HDAC2HDAC6VNN1 | |
| SCHEMBL30801504 | 0.67 | HDAC1 (0.68) | HDAC3HDAC1HDAC2HDAC6VNN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | HDAC3 2899/4885HDAC1 3559/4885HDAC2 2918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.